Allergy: A risk factor for suicide?

Mann JJ: Neurobiology of suicidal behaviour. Nat Rev Neurosci 2003, 4: 819–828.

Goodwin FK, Jamison KR: Manic Depressive Illness: Bipolar Disorders and Recurrent Depression, edn 2. New York: Oxford University Press; 2007.

American Academy of Allergy Asthma & Immunology: National Allergy Bureau. Available at http://www.aaaai.org/nab/index.cfm . Accessed June 19, 2008.

Kosisky SE, Carpenter GB: Predominant tree aeroallergens of the Washington, DC area: a six year survey (1989–1994) Ann Allergy Asthma Immunol 1997, 78: 381–392.

Postolache TT, Stiller JW, Herrell R, et al.: Tree pollen peaks are associated with increased nonviolent suicide in women. Mol Psychiatry 2005, 10: 232–235.

Timonen M, Jokelainen J, Hakko H, et al.: Atopy and depression: results from the Northern Finland 1966 Birth Cohort Study. Mol Psychiatry 2003, 8: 738–744.

Marshall PS, O’Hara C, Steinberg P: Effects of seasonal allergic rhinitis on fatigue levels and mood. Psychosom Med 2002, 64: 684–691.

Guzman A, Tonelli LH, Roberts D, et al.: Mood-worsening with high-pollen-counts and seasonality: a preliminary report. J Affect Disord 2007, 101: 269–274.

Postolache TT, Lapidus M, Sander ER, et al.: Changes in allergy symptoms and depression scores are positively correlated in patients with recurrent mood disorders exposed to seasonal peaks in aeroallergens. ScientificWorldJournal 2007, 7: 1968–1977.

Postolache TT, Langenberg PB, Zimmerman SA, et al.: Changes in severity of allergy and anxiety symptoms are positively correlated in patients with recurrent mood disorders who are exposed to seasonal peaks of aeroallergens. Int J Child Health Hum Dev (in press).

Bell IR, Jasnoski ML, Kagan J, et al.: Depression and allergies: survey of a nonclinical population. Psychother Psychosom 1991, 55: 24–31.

Hashiro M, Okumura M: The relationship between the psychological and immunological state in patients with atopic dermatitis. J Dermatol Sci 1998, 16: 231–235.

Timonen M, Jokelainen J, Silvennoinen-Kassinen S, et al.: Association between skin test diagnosed atopy and professionally diagnosed depression: a Northern Finland 1966 Birth Cohort study. Biol Psychiatry 2002, 52: 349–355.

Timonen M, Jokelainen J, Herva A, et al.: Presence of atopy in first-degree relatives as a predictor of a female proband’s depression: results from the Northern Finland 1966 Birth Cohort. J Allergy Clin Immunol 2003, 111: 1249–1254.

Wamboldt MZ, Hewitt JK, Schmitz S, et al.: Familial association between allergic disorders and depression in adult Finnish twins. Am J Med Genet 2000, 96: 146–153.

Wilken JA, Berkowitz R, Kane R: Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 2002, 89: 372–380.

Hurwitz EL, Morgenstern H: Cross-sectional associations of asthma, hay fever, and other allergies with major depression and low-back pain among adults aged 20–39 years in the United States. Am J Epidemiol 1999, 150: 1107–1116.

Addolorato G, Ancona C, Capristo E, et al.: State and trait anxiety in women affected by allergic and vasomotor rhinitis. J Psychosom Res 1999, 46: 283–289.

Prolo P, Licinio J: Cytokines in affective disorders and schizophrenia: new clinical and genetic findings. Mol Psychiatry 1999, 4: 396.

Capuron L, Ravaud A, Gualde N, et al.: Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 2001, 26: 797–808.

Dantzer R, Wollman EE, Yirmiya R: Cytokines and depression: an update. Brain Behav Immun 2002, 16: 501–502.

Capuron L, Dantzer R: Cytokines and depression: the need for a new paradigm. Brain Behav Immun 2003, 17(Suppl 1): S119–S124.

Anisman H, Merali Z, Poulter MO, et al.: Cytokines as a precipitant of depressive illness: animal and human studies. Curr Pharm Des 2005, 11: 963–972.

Schiepers OJ, Wichers MC, Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29: 201–217.

Raison CL, Capuron L, Miller AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006, 27: 24–31.

Dantzer R, Kelley KW: Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007, 21: 153–160.

Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000, 157: 867–876.

Crone CC, Gabriel GM, Wise TN: Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C. Cleve Clin J Med 2004, 71(Suppl 3): S27–S32.

Raison CL, Demetrashvili M, Capuron L, et al.: Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005, 19: 105–123.

Denicoff KD, Rubinow DR, Papa MZ, et al.: The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987, 107: 293–300.

Capuron L, Ravaud A, Dantzer R: Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 2000, 18: 2143–2151.

Capuron L, Dantzer R, Miller AH: Neuro-immune interactions in psychopathology with the example of interferon alpha-induced depression. J Soc Biol 2003, 197: 151–156.

Frommberger UH, Bauer J, Haselbauer P, et al.: Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997, 247: 228–233.

Levine J, Barak Y, Chengappa KN, et al.: Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 1999, 40: 171–176.

Yirmiya R, Weidenfeld J, Pollack Y, et al.: Cytokines, “depression due to a general medical condition,” and antidepressant drugs. Adv Exp Med Biol 1999, 461: 283–316.

Dunn AJ, Swiergiel AH, de Beaurepaire R: Cytokines as mediators of depression: What can we learn from animal studies? Neurosci Biobehav Rev 2005, 29: 891–909.

Dunn AJ, Swiergiel AH: Effects of interleukin-1 and endotoxin in the forced swim and tail suspension tests in mice. Pharmacol Biochem Behav 2005, 81: 688–693.

Swiergiel AH, Dunn AJ: Effects of interleukin-1beta and lipopolysaccharide on behavior of mice in the elevated plusmaze and open field tests. Pharmacol Biochem Behav 2007, 86: 651–659.

Reichenberg A, Yirmiya R, Schuld A, et al.: Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001, 58: 445–452.

De La Garza R: Endotoxin-or pro-inflammatory cytokine-induced sickness behavior as an animal model of depression: focus on anhedonia. Neurosci Biobehav Rev 2005, 29: 761–770.

Engeland CG, Kavaliers M, Ossenkopp KP: Sex differences in the effects of muramyl dipeptide and lipopolysaccharide on locomotor activity and the development of behavioral tolerance in rats. Pharmacol Biochem Behav 2003, 74: 433–447.

Tonelli LH, Stiller J, Rujescu D, et al.: Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr Scand 2008, 117: 198–206.

Tonelli LH, Holmes A, Postolache TT: Intranasal immune challenge induces sex-dependent depressive-like behavior and cytokine expression in the brain. Neuropsychopharmacology 2008, 33: 1038–1048.

Tonelli LH, Virk G, Joppy B, et al.: Experimentally induced allergy to tree pollen induces depressive-like behavior and mast cell activation in the brain of female rats. Society of Biological Psychiatry Annual Meeting, Toronto, Canada; 2006.

Tonelli LH, Hoshino A, Katz M, et al.: Acute stress promotes aggressive-like behavior in rats made allergic to tree pollen. Int J Child Health Hum Dev (in press).

Goehler LE, Gaykema RP, Hansen MK, et al.: Vagal immune-to-brain communication: a visceral chemosensory pathway. Auton Neurosci 2000, 85: 49–59.

Quan N, Herkenham M: Connecting cytokines and brain: a review of current issues. Histol Histopathol 2002, 17: 273–288.

Pitossi F, del Ray A, Kabiersch A, et al.: Induction of cytokine transcripts in the central nervous system and pituitary following peripheral administration of endotoxin to mice. J Neurosci Res 1997, 48: 287–298.

Molina-Holgado F, Toulmond S, Rothwell NJ: Involvement of interleukin-1 in glial responses to lipopolysaccharide: endogenous versus exogenous interleukin-1 actions. J Neuroimmunol 2000, 111: 1–9.

Turrin NP, Plata-Salamán CR: Cytokine-cytokine interactions and the brain. Brain Res Bull 2000, 51: 3–9.

Vitkovic L, Konsman JP, Bockaert J, et al.: Cytokine signals propagate through the brain. Mol Psychiatry 2000, 5: 604–615.

Rivest S: Molecular insights on the cerebral innate immune system. Brain Behav Immun 2003, 17: 13–19.

Turnbull AV, Rivier C: Regulation of the HPA axis by cytokines. Brain Behav Immun 1995, 9: 253–275.

Tonelli LH, Postolache TT, Sternberg EM: Inflammatory genes and neural activity: involvement of immune genes in synaptic function and behavior. Front Biosci 2005, 10: 675–680.

Quan N, Zhang Z, Demetrikopoulos MK: Evidence for involvement of B lymphocytes in the surveillance of lung metastasis in the rat. Cancer Res 1999, 59: 1080–1089.

Tonelli LH, Maeda S, Rapp KL, et al.: Differential induction of interleukin-I beta mRNA in the brain parenchyma of Lewis and Fischer rats after peripheral injection of lipopolysaccharides. J Neuroimmunol 2003, 140: 126–136.

Tonelli LH, Postolache TT: Tumor necrosis factor alpha, interleukin-1 beta, interleukin-6 and major histocompatibility complex molecules in the normal brain and after peripheral immune challenge. Neurol Res 2005, 27: 679–684.

Singareddy RK, Balon R: Sleep and suicide in psychiatric patients. Ann Clin Psychiatry 2001, 13: 93–101.

Fawcett J, Scheftner WA, Fogg L, et al.: Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990, 147: 1189–1194.

Krueger JM, Walter J, Dinarello CA, et al.: Sleep-promoting effects of endogenous pyrogen (interleukin-1). Am J Physiol 1984, 246: R994–R999.

Opp MR, Krueger JM: Interleukin 1-receptor antagonist blocks interleukin 1-induced sleep and fever. Am J Physiol 1991, 260: R453–R457.

Kapas L, Krueger JM: Tumor necrosis factor-beta induces sleep, fever, and anorexia. Am J Physiol 1992, 263: R703–R707.

Gemma C, Imeri L, de Simoni MG, et al.: Interleukin-1 induces changes in sleep, brain temperature, and serotonergic metabolism. Am J Physiol 1997, 272: R601–R606.

Hogan D, Morrow JD, Smith EM, et al.: Interleukin-6 alters sleep of rats. J Neuroimmunol 2003, 137: 59–66.

Kushikata T, Fang J, Wang Y, Krueger JM: Interleukin-4 inhibits spontaneous sleep in rabbits. Am J Physiol 1998, 275: R1185–R1191.

Kushikata T, Fang J, Krueger JM: Interleukin-10 inhibits spontaneous sleep. J Interferon Cytokine Res 1999, 19: 1025–1030.

Vgontzas AN, Chrousos GP: Sleep, the hypothalamicpituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders. Endocrinol Metab Clin North Am 2002, 31: 15–36.

Hughes K, Glass C, Ripchinski M, et al.: Efficacy of the topical nasal steroid budesonide on improving sleep and daytime somnolence in patients with perennial allergic rhinitis. Allergy 2003, 58: 380–385.

Hamano N, Terada N, Maesako K, et al.: Effect of sex hormones on eosinophilic inflammation in nasal mucosa. Allergy Asthma Proc 1998, 19: 263–269.

Vliagoftis H, Dimitriadou V, Boucher W, et al.: Estradiol augments while tamoxifen inhibits rat mast cell secretion. Int Arch Allergy Immunol 1992, 98: 398–409.

Osman M: Therapeutic implications of sex differences in asthma and atopy. Arch Dis Child 2003, 88: 587–590.

Illum L: Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004, 56: 3–17.

Thorne RG, Pronk GJ, Padmanabhan V: Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004, 127: 481–496.

Mori I, Goshima F, Ito H, et al.: The vomeronasal chemosensory system as a route of neuroinvasion by herpes simplex virus. Virology 2005, 334: 51–58.

Loftus LT, Li HF, Gray AJ, et al.: In vivo protein transduction to the CNS. Neuroscience 2006, 139: 1061–1067.

Kalueff AV, Lehtimaki KA, Ylinen A, et al.: Intranasal administration of human IL-6 increases the severity of chemically induced seizures in rats. Neurosci Lett 2004, 365: 106–110.

Pelidou SH, Zou LP, Deretzi G, et al.: Enhancement of acute phase and inhibition of chronic phase of experimental autoimmune neuritis in Lewis rats by intranasal administration of recombinant mouse interleukin 17: potential immunoregulatory role. Exp Neurol 2000, 163: 165–172.

Annesi-Maesano I: Epidemiological evidence of the occurrence of rhinitis and sinusitis in asthmatics. Allergy 1999, 54(Suppl 57): 7–13.

Dykewicz MS, Fineman S, Skoner DP, et al.: Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998, 81: 478–518.

The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee: Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998, 351: 1225–1232.

Bousquet J, Van Cauwenberge P, Khaltaev N: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001, 108(5 Suppl): S147–S334.

Dykewicz MS: Rhinitis and sinusitis. J Allergy Clin Immunol 2003, 111(2 Suppl): S520–S529.

Demoly P, Allaert FA, Lecasble M, Bousquet J: Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy 2003, 58: 672–675.

Ku M, Silverman B, Prifti N, et al.: Prevalence of migraine headaches in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2006, 97: 226–230.

Low NC, Merikangas KR: The comorbidity of migraine. CNS Spectr 2003, 8: 433–434, 437–444.

Frediani T, Lucarelli S, Pelliccia A, et al.: Allergy and childhood epilepsy: a close relationship? Acta Neurol Scand 2001, 104: 349–352.

Theoharides TC, Donelan J, Kandere-Grzybowska, et al.: The role of mast cells in migraine pathophysiology. Brain Res Rev 2005, 49: 65–76.

Boyce JA; Mast cells: beyond IgE. J Allergy Clin Immunol 2003, 111: 24–32.

Berger WE: Treatment update: allergic rhinitis. Allergy Asthma Proc 2001, 22: 191–198.

Borish L: Allergic rhinitis: systemic inflammation and implications for management. J Allergy Clin Immunol 2003, 112: 1021–1031.

Hamilton RG, Adkinson NF Jr.: Clinical laboratory assessment of IgE-dependent hypersensitivity. J Allergy Clin Immunol 2003, 111(2 Suppl): S687–S701.

Tomooka LT, Murphy C, Davidson TM: Clinical study and literature review of nasal irrigation. Laryngoscope 2000, 110: 1189–1193.

Weiner JM, Abramson MJ, Puy RM: Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998, 317: 1624–1629.

Yàñez A, Rodrigo GJ: Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002, 89: 479–484.

Rodrigo GJ, Yàñez A: The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol 2006, 96: 779–786.

Chait LD: Factors influencing the reinforcing and subjective effects of ephedrine in humans. Psychopharmacology (Berl) 1994, 113: 381–387.

Meltzer EO, Weiler JM, Widlitz MD: Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 1996, 97: 617–626.

US Food and Drug Administration: Early communication about an ongoing safety review of montelukast (Singulair). March 27, 2008. Available at http://www.fda.gov/cder/drug/early_comm/montelukast.htm

Brozek JL, Baena-Cagnani CE, Bonini S, et al.: Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update. Allergy 2008, 63: 38–46.

Calderon MA, Alves B, Jacobson M, et al.: Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007, CD001936.

Radulovic S, Calderon MA, Wilson DR, et al.: Safety profile of sublingual immunotherapy (SLIT) for allergic rhinitis (AR). J Allergy Clin Immun 2008, 121: S142.

Didier A, Malling H, Worm M, et al.: Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007, 120: 1338–1345.

Kaliner MA: Omalizumab and the treatment of allergic rhinitis. Curr Allergy Asthma Rep 2004, 4: 237–244.